Wall Street analysts predict that IMV Inc. (NASDAQ:IMV) will post earnings per share (EPS) of ($0.13) for the current quarter, according to Zacks. Zero analysts have issued estimates for IMV’s earnings. The lowest EPS estimate is ($0.16) and the highest is ($0.10). IMV reported earnings of ($0.10) per share in the same quarter last year, which would indicate a negative year over year growth rate of 30%. The company is scheduled to announce its next earnings results on Thursday, November 11th.
On average, analysts expect that IMV will report full-year earnings of ($0.39) per share for the current financial year, with EPS estimates ranging from ($0.53) to ($0.27). For the next fiscal year, analysts expect that the company will report earnings of ($0.47) per share, with EPS estimates ranging from ($0.76) to ($0.23). Zacks’ earnings per share averages are a mean average based on a survey of sell-side analysts that that provide coverage for IMV.
IMV (NASDAQ:IMV) last issued its quarterly earnings data on Wednesday, August 11th. The company reported ($0.11) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.12) by $0.01. IMV had a negative return on equity of 99.76% and a negative net margin of 11,386.18%. The business had revenue of $0.04 million for the quarter.
Shares of IMV stock traded up $0.01 during mid-day trading on Friday, reaching $1.63. The stock had a trading volume of 16,257 shares, compared to its average volume of 237,358. The firm’s 50 day simple moving average is $1.68 and its 200 day simple moving average is $2.13. The company has a quick ratio of 5.11, a current ratio of 5.11 and a debt-to-equity ratio of 0.38. IMV has a one year low of $1.31 and a one year high of $4.60. The firm has a market cap of $133.89 million, a PE ratio of -3.88 and a beta of 1.49.
Several large investors have recently made changes to their positions in IMV. Virtu Financial LLC acquired a new stake in IMV during the 2nd quarter worth about $45,000. Millennium Management LLC bought a new position in IMV in the 2nd quarter valued at about $69,000. Renaissance Technologies LLC bought a new position in IMV in the 2nd quarter valued at about $70,000. LexAurum Advisors LLC bought a new position in IMV in the 2nd quarter valued at about $72,000. Finally, JPMorgan Chase & Co. bought a new position in IMV in the 2nd quarter valued at about $88,000. Institutional investors own 11.01% of the company’s stock.
IMV, Inc is a clinical-stage biopharmaceutical company that engages in providing a novel class of cancer immunotherapies and vaccines against infectious diseases including COVID-19. The company leverages its delivery platform (DPX) that programs immune cells directly within the human body to produce robust and sustained target killing capabilities.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for IMV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IMV and related companies with MarketBeat.com's FREE daily email newsletter.